More than 400 participants represented dozens of manufacturing companies with diversified educational background & experience attended throughout the day with active participation in discussion forum of Regulatory & Quality Sciences.
From Terminal Sterlization to Aseptic Manufacturing of Perentral Products: Gu...Obaid Ali / Roohi B. Obaid
This document provides an overview of terminal sterilization versus aseptic manufacturing of parenteral products. It discusses various challenges related to microorganisms like their ability to form spores, sensitivity to heat/radiation/chemicals, and whether they are aerobic/anaerobic. It notes that aseptic processing provides increased separation of personnel and confidence in sterility assurance compared to conventional methods. The document emphasizes taking a proactive approach to risk management and quality assurance to better understand processes and assure patient safety.
The document discusses the objectives and topics of a discussion forum on pharmaceutical engineering related to designing and maintenance of pharmaceutical manufacturing facilities. The main objectives are to provide an interface among multidisciplinary teams to discuss science and regulations in a common language, and to provide an opportunity for knowledge sharing and transfer among pharmaceutical professionals from different educational backgrounds. The forum will also serve as a platform for engineers to exchange knowledge and learn about expanding regulatory expectations. The opening talk will be given by the Deputy Director of the Drug Regulatory Authority of Pakistan and will focus on regulatory experience and knowledge sharing without obligation on the regulatory agency. Some of the specific topics to be discussed include design principles in relation to GMP standards, importance of cleaning and maintenance, facility layout designs
This document summarizes a presentation on quality metrics and culture given at Habib University in Karachi. It discusses key quality metrics like lot acceptance rate, product complaint rate, and CAPA effectiveness. It also identifies attributes of a strong quality culture like leadership emphasis, message credibility, peer involvement, and employee ownership. Finally, it stresses that quality is everyone's responsibility and a mature quality system relies on systems thinking and a culture that prioritizes quality and continuous improvement.
This document discusses the design, trust, and control of sterile manufacturing. It begins with opening questions about which dosage form approaches vital organs fastest (injection), which manufacturing area requires the highest control of particles and microorganisms (injection manufacturing), and which defect is most difficult to detect (contamination). The document then provides an overview of inherent challenges in sterile manufacturing and notes that injectables are easy to formulate but difficult to manufacture due to the need for strict control of contamination. It emphasizes that contamination in injectables can lead to serious health consequences since injections take effect rapidly and potential issues may not be reversible. The document stresses that particles and microbial contamination present a continuous challenge in sterile manufacturing.
1) The document summarizes a training session on Good Manufacturing Practices (GMP) of the 21st Century that focused on continuous manufacturing, data sciences, machine learning, and real time release.
2) It discusses that traditional quality practices are no longer sufficient and that transformation is needed to address increasing complexity and uncertainty in pharmaceutical manufacturing.
3) The document questions whether one-time process validation on 3 batches and a single bioavailability/bioequivalence study are sufficient to assure quality over a product's lifecycle.
SMi Group's Pharmaceutical Microbiology East Coast 2017 conferenceDale Butler
This document provides information on a workshop titled "Navigating the requirements of a modern QC Microbiology Laboratory" that will be held on November 15th, 2017. The workshop will introduce approaches for blending traditional and cutting-edge microbiology methodologies both in the laboratory and for manufacturing monitoring programs. It will also provide practical solutions for common laboratory issues and expectations for building quality into pharmaceutical products. The workshop will be led by Vanessa Vasadi-Figueroa and Robert Ferer and cover topics such as modernizing laboratories, real-time release testing, data integrity, and training new talent.
Deibel Laboratories has been providing food and personal care product testing services for over 30 years through a network of 12 laboratories across the US that operate 365 days a year. They take a partnership approach to working with clients by providing personalized support to help ensure product quality and safety rather than just reporting results. Many food producers and companies trust Deibel Labs for their quality control protocols, scientific integrity, and customer service to protect their brand names.
From Terminal Sterlization to Aseptic Manufacturing of Perentral Products: Gu...Obaid Ali / Roohi B. Obaid
This document provides an overview of terminal sterilization versus aseptic manufacturing of parenteral products. It discusses various challenges related to microorganisms like their ability to form spores, sensitivity to heat/radiation/chemicals, and whether they are aerobic/anaerobic. It notes that aseptic processing provides increased separation of personnel and confidence in sterility assurance compared to conventional methods. The document emphasizes taking a proactive approach to risk management and quality assurance to better understand processes and assure patient safety.
The document discusses the objectives and topics of a discussion forum on pharmaceutical engineering related to designing and maintenance of pharmaceutical manufacturing facilities. The main objectives are to provide an interface among multidisciplinary teams to discuss science and regulations in a common language, and to provide an opportunity for knowledge sharing and transfer among pharmaceutical professionals from different educational backgrounds. The forum will also serve as a platform for engineers to exchange knowledge and learn about expanding regulatory expectations. The opening talk will be given by the Deputy Director of the Drug Regulatory Authority of Pakistan and will focus on regulatory experience and knowledge sharing without obligation on the regulatory agency. Some of the specific topics to be discussed include design principles in relation to GMP standards, importance of cleaning and maintenance, facility layout designs
This document summarizes a presentation on quality metrics and culture given at Habib University in Karachi. It discusses key quality metrics like lot acceptance rate, product complaint rate, and CAPA effectiveness. It also identifies attributes of a strong quality culture like leadership emphasis, message credibility, peer involvement, and employee ownership. Finally, it stresses that quality is everyone's responsibility and a mature quality system relies on systems thinking and a culture that prioritizes quality and continuous improvement.
This document discusses the design, trust, and control of sterile manufacturing. It begins with opening questions about which dosage form approaches vital organs fastest (injection), which manufacturing area requires the highest control of particles and microorganisms (injection manufacturing), and which defect is most difficult to detect (contamination). The document then provides an overview of inherent challenges in sterile manufacturing and notes that injectables are easy to formulate but difficult to manufacture due to the need for strict control of contamination. It emphasizes that contamination in injectables can lead to serious health consequences since injections take effect rapidly and potential issues may not be reversible. The document stresses that particles and microbial contamination present a continuous challenge in sterile manufacturing.
1) The document summarizes a training session on Good Manufacturing Practices (GMP) of the 21st Century that focused on continuous manufacturing, data sciences, machine learning, and real time release.
2) It discusses that traditional quality practices are no longer sufficient and that transformation is needed to address increasing complexity and uncertainty in pharmaceutical manufacturing.
3) The document questions whether one-time process validation on 3 batches and a single bioavailability/bioequivalence study are sufficient to assure quality over a product's lifecycle.
SMi Group's Pharmaceutical Microbiology East Coast 2017 conferenceDale Butler
This document provides information on a workshop titled "Navigating the requirements of a modern QC Microbiology Laboratory" that will be held on November 15th, 2017. The workshop will introduce approaches for blending traditional and cutting-edge microbiology methodologies both in the laboratory and for manufacturing monitoring programs. It will also provide practical solutions for common laboratory issues and expectations for building quality into pharmaceutical products. The workshop will be led by Vanessa Vasadi-Figueroa and Robert Ferer and cover topics such as modernizing laboratories, real-time release testing, data integrity, and training new talent.
Deibel Laboratories has been providing food and personal care product testing services for over 30 years through a network of 12 laboratories across the US that operate 365 days a year. They take a partnership approach to working with clients by providing personalized support to help ensure product quality and safety rather than just reporting results. Many food producers and companies trust Deibel Labs for their quality control protocols, scientific integrity, and customer service to protect their brand names.
This presentation discusses creating a sustainable culture of quality in the pharmaceutical industry. It covers topics such as what good manufacturing practices (GMP) are and how they help ensure drug quality and safety. The presentation notes several past drug contamination incidents that harmed or killed patients. It emphasizes that quality cannot be tested into products but must be built into the manufacturing process. The presentation also discusses quality culture and attributes like leadership, continuous improvement, and understanding human behavior and motivations. The overall message is that a robust quality system and culture are needed to avoid quality issues and protect patients.
The document discusses creating a sustainable culture of quality in the pharmaceutical industry. It provides examples of key quality metrics such as lot acceptance rate, product quality complaint rate, and invalidated OOS rate that can be used to measure the state of quality. It also identifies attributes that are essential for a quality culture, such as leadership emphasis on quality, message credibility, peer involvement, and employee ownership. The document emphasizes that a strong quality culture is needed to support an efficient quality system and outlines some of the visible signals and roots of a strong quality culture.
Presented to a small group of working professionals (Constructed from different documents of FDA, ISPE etc. available on public domain) - Personal point of view
75 min presentation in program organized by Gudia (Pvt.) Ltd Pakistan & Dr. P...Obaid Ali / Roohi B. Obaid
This document summarizes a presentation on pharmaceutical manufacturing given by Roohi B. Obaid. The presentation discusses issues like product recalls due to contamination, the importance of understanding manufacturing processes and their impact on product quality, and establishing a quality culture. It emphasizes having a robust quality system, challenging assumptions, learning from mistakes, and ensuring products meet their intended quality through testing and metrics. The overall goal is consistently delivering safe, effective medicines to patients.
Cleaning Validation in Pharmaceutical Manufacturing - A Regulatory Perspectiv...Obaid Ali / Roohi B. Obaid
1. Cleaning validation in pharmaceutical manufacturing is important from a regulatory perspective to control contamination and cross-contamination.
2. Contamination can occur during manufacturing processes and proper cleaning between batches of different products or therapeutic classes is necessary to preserve purity and control impurities.
3. Inadequate cleaning procedures, validation studies, and contamination investigations have led to regulatory actions against companies by authorities like the FDA.
Based on the scenario provided, here are the key steps I would recommend the finished goods manufacturer take:
1. Immediately notify the relevant regulatory authorities of the potential contamination issue and put all affected batches of finished product on hold.
2. Conduct a thorough investigation to determine the extent of contamination and identify which batches of API and finished product may be impacted. This should include testing retained samples.
3. Recall all affected batches of finished product that may contain terazosin contamination from the supply chain and inform customers.
4. Develop and implement a risk mitigation and communication plan to address potential safety issues and prevent further distribution of contaminated product.
5. Review manufacturing and quality control processes to identify any gaps that allowed
The filling machine and HEPA filter located directly above the filling machine in the filling room were significantly discolored with an unknown substance. This indicates potential contamination issues that need to be investigated and addressed. Facilities should ensure machinery and equipment are properly cleaned and maintained to prevent contamination that could compromise product quality.
This document provides an introduction and overview of a training session on Good Manufacturing Practices (GMP) for the 21st century. It notes that the presentation will reflect the presenter's views and is not meant to represent any official policies. Examples of recent drug contamination and mix-ups are presented to illustrate the importance of GMP in ensuring consistent quality, preventing contamination and mix-ups. GMP is described as a set of regulatory methods to inspect manufacturing practices to protect the integrity and quality of products intended for human use and ensure they are consistently produced and controlled.
This document discusses quality systems in manufacturing facilities. It begins with an overview of fundamental quality issues that have led to tragedies in healthcare products. The discussion then focuses on quality attributes and how ensuring safety, efficacy, identity, purity, strength and consistency are critical. Several case studies on quality failures at manufacturing sites are presented to demonstrate how deficiencies can occur when quality systems are not adequately implemented and maintained. The importance of compliance with good manufacturing practices to ensure quality is built into the manufacturing process is emphasized.
This document discusses cleaning validation and contamination control in the pharmaceutical manufacturing process. It addresses the importance of cleaning equipment to prevent mix-ups, cross-contamination, microbial growth, and inconsistency between batches. Cleaning procedures, sampling methods, analytical methods, and establishment of acceptance limits are key aspects of a cleaning validation program. The document also highlights potential issues that may arise, such as inadequate cleaning procedures, operator performance issues, and failure to properly investigate deviations or out-of-specification results. Maintaining cleaning records and batch-to-batch consistency is important for regulatory compliance.
1. A manufacturer recalled one of their products after 36 containers from a particular lot were found contaminated with mold. Complaints about the product included chemical smells, mold complaints, and stinging for the cream.
2. Questions were raised about why every complaint was not documented and why the investigation was not extended to other lots. A comprehensive independent review of the company's quality systems and documentation was recommended.
3. GMP compliance revolves around consistency, preventing mix-ups and contamination, ensuring product strength and purity, and maintaining traceability and integrity throughout the manufacturing process. Non-compliance can result in issues like cosmetic problems, hospitalization, or death.
This document summarizes a presentation on managing regulatory requirements for drug quality using science-based approaches. The presentation discusses past drug safety issues and recalls to emphasize the importance of understanding products and processes. It promotes establishing a quality culture where patient safety and quality are prioritized. Various quality metrics and tools are presented to systematically evaluate manufacturing processes and establish appropriate controls to prevent issues. Real-world case studies of drug recalls and failures are analyzed to demonstrate how problems can be avoided through knowledge management and quality risk management approaches.
The document summarizes the key aspects of Shaklee products, including their focus on natural ingredients, extensive testing and research, and health benefits shown in clinical studies. It highlights features such as no artificial flavors, sweeteners, or fillers and being chlorine bleach free. The summary also notes Shaklee's investment in research and development, product guarantees, and supplement options for nutrition, weight management, and home cleaning.
The document summarizes the key aspects of Shaklee products, including their focus on natural ingredients, extensive testing and research, and health benefits shown in clinical studies. Some highlights include over 50 years of proven success with natural products, $250 million invested in research and development, and a landmark study showing long-term Shaklee supplement users had better health than non-users.
This document provides an overview of cannabis products and sales training. It discusses topics such as Colorado cannabis laws, health and safety standards, identifying customers and checking IDs, privacy practices, effects of cannabis, recommending different cannabis products like flower, edibles, concentrates, and alternatives. It also covers dispensary basics, gauging consumer tolerance, potency and dosing, product weight conversions, and restrictions on how much product can be sold. The textbook aims to educate cannabis sales associates and limit the spread of misinformation.
The document discusses several topics related to improving drug quality including:
1) Evidence from clinical trials and real world use is key to determining drug effectiveness but quality can deteriorate after marketing authorization without a strong quality management system.
2) Errors must be eliminated through quality by design in development and operational excellence, and companies must continuously improve rather than just fixing problems.
3) Digital transformation, identifying critical quality attributes, and moving to more flexible and integrated quality systems will help address issues and improve patient outcomes.
India's first Int'l Conference on Best Practices in Pharma Microbiology Biocon
This is the first time that Pharmig, an international Pharmaceutical Microbiology think tank based out of the UK is organizing a conference on the "Best Practices in Pharma Microbiology" for the first time in India. You can register
by sending an email to maxine@pharmig.org.uk. For booking a seat for the conference, please visit: http://bit.ly/1J4gtLh
This document discusses several challenges related to ensuring quality in Good Manufacturing Practices (GMP) and drug production, including issues with variability, contamination, and integrity. It notes that quality is complex and can be influenced by many factors across different functions. Oversight from reviewers, inspectors, and integrated teams is important. Collaboration between companies and governments is also key when it comes to labeling, agreements, and research review. The quality of drugs cannot be easily tested, so adherence to GMP regarding ingredients, facilities, and manufacturing processes is critical.
The document discusses anti-thymocyte globulin (ATG), which is used for acute organ rejection. ATG is produced from rabbits that are inoculated with human T lymphocytes to trigger an antibody response. The antibodies produced in rabbits are then extracted, purified, and administered to patients to kill arrays of lymphocytes. Developing a process to characterize the target globulin and transferring knowledge will help establish protein production. Key challenges include maintaining clean environments and aseptic extraction, purification, and filling processes.
The document discusses establishing the OR Centre for Quality Sciences to provide consulting services to the pharmaceutical and biologics industries regarding quality, regulatory affairs, innovation, and technology. It aims to engage subject matter experts to support academia, industry, and government. The Centre will focus on shifting from a compliance to a quality culture and aligning with new regulatory expectations in a changing technological landscape with advances in areas like artificial intelligence and data sciences. It will provide training, reviews, audits, and other services to support quality systems, documentation practices, regulatory submissions, clinical trials, and more.
More Related Content
Similar to Opening Talk and Interactive Discussion
This presentation discusses creating a sustainable culture of quality in the pharmaceutical industry. It covers topics such as what good manufacturing practices (GMP) are and how they help ensure drug quality and safety. The presentation notes several past drug contamination incidents that harmed or killed patients. It emphasizes that quality cannot be tested into products but must be built into the manufacturing process. The presentation also discusses quality culture and attributes like leadership, continuous improvement, and understanding human behavior and motivations. The overall message is that a robust quality system and culture are needed to avoid quality issues and protect patients.
The document discusses creating a sustainable culture of quality in the pharmaceutical industry. It provides examples of key quality metrics such as lot acceptance rate, product quality complaint rate, and invalidated OOS rate that can be used to measure the state of quality. It also identifies attributes that are essential for a quality culture, such as leadership emphasis on quality, message credibility, peer involvement, and employee ownership. The document emphasizes that a strong quality culture is needed to support an efficient quality system and outlines some of the visible signals and roots of a strong quality culture.
Presented to a small group of working professionals (Constructed from different documents of FDA, ISPE etc. available on public domain) - Personal point of view
75 min presentation in program organized by Gudia (Pvt.) Ltd Pakistan & Dr. P...Obaid Ali / Roohi B. Obaid
This document summarizes a presentation on pharmaceutical manufacturing given by Roohi B. Obaid. The presentation discusses issues like product recalls due to contamination, the importance of understanding manufacturing processes and their impact on product quality, and establishing a quality culture. It emphasizes having a robust quality system, challenging assumptions, learning from mistakes, and ensuring products meet their intended quality through testing and metrics. The overall goal is consistently delivering safe, effective medicines to patients.
Cleaning Validation in Pharmaceutical Manufacturing - A Regulatory Perspectiv...Obaid Ali / Roohi B. Obaid
1. Cleaning validation in pharmaceutical manufacturing is important from a regulatory perspective to control contamination and cross-contamination.
2. Contamination can occur during manufacturing processes and proper cleaning between batches of different products or therapeutic classes is necessary to preserve purity and control impurities.
3. Inadequate cleaning procedures, validation studies, and contamination investigations have led to regulatory actions against companies by authorities like the FDA.
Based on the scenario provided, here are the key steps I would recommend the finished goods manufacturer take:
1. Immediately notify the relevant regulatory authorities of the potential contamination issue and put all affected batches of finished product on hold.
2. Conduct a thorough investigation to determine the extent of contamination and identify which batches of API and finished product may be impacted. This should include testing retained samples.
3. Recall all affected batches of finished product that may contain terazosin contamination from the supply chain and inform customers.
4. Develop and implement a risk mitigation and communication plan to address potential safety issues and prevent further distribution of contaminated product.
5. Review manufacturing and quality control processes to identify any gaps that allowed
The filling machine and HEPA filter located directly above the filling machine in the filling room were significantly discolored with an unknown substance. This indicates potential contamination issues that need to be investigated and addressed. Facilities should ensure machinery and equipment are properly cleaned and maintained to prevent contamination that could compromise product quality.
This document provides an introduction and overview of a training session on Good Manufacturing Practices (GMP) for the 21st century. It notes that the presentation will reflect the presenter's views and is not meant to represent any official policies. Examples of recent drug contamination and mix-ups are presented to illustrate the importance of GMP in ensuring consistent quality, preventing contamination and mix-ups. GMP is described as a set of regulatory methods to inspect manufacturing practices to protect the integrity and quality of products intended for human use and ensure they are consistently produced and controlled.
This document discusses quality systems in manufacturing facilities. It begins with an overview of fundamental quality issues that have led to tragedies in healthcare products. The discussion then focuses on quality attributes and how ensuring safety, efficacy, identity, purity, strength and consistency are critical. Several case studies on quality failures at manufacturing sites are presented to demonstrate how deficiencies can occur when quality systems are not adequately implemented and maintained. The importance of compliance with good manufacturing practices to ensure quality is built into the manufacturing process is emphasized.
This document discusses cleaning validation and contamination control in the pharmaceutical manufacturing process. It addresses the importance of cleaning equipment to prevent mix-ups, cross-contamination, microbial growth, and inconsistency between batches. Cleaning procedures, sampling methods, analytical methods, and establishment of acceptance limits are key aspects of a cleaning validation program. The document also highlights potential issues that may arise, such as inadequate cleaning procedures, operator performance issues, and failure to properly investigate deviations or out-of-specification results. Maintaining cleaning records and batch-to-batch consistency is important for regulatory compliance.
1. A manufacturer recalled one of their products after 36 containers from a particular lot were found contaminated with mold. Complaints about the product included chemical smells, mold complaints, and stinging for the cream.
2. Questions were raised about why every complaint was not documented and why the investigation was not extended to other lots. A comprehensive independent review of the company's quality systems and documentation was recommended.
3. GMP compliance revolves around consistency, preventing mix-ups and contamination, ensuring product strength and purity, and maintaining traceability and integrity throughout the manufacturing process. Non-compliance can result in issues like cosmetic problems, hospitalization, or death.
This document summarizes a presentation on managing regulatory requirements for drug quality using science-based approaches. The presentation discusses past drug safety issues and recalls to emphasize the importance of understanding products and processes. It promotes establishing a quality culture where patient safety and quality are prioritized. Various quality metrics and tools are presented to systematically evaluate manufacturing processes and establish appropriate controls to prevent issues. Real-world case studies of drug recalls and failures are analyzed to demonstrate how problems can be avoided through knowledge management and quality risk management approaches.
The document summarizes the key aspects of Shaklee products, including their focus on natural ingredients, extensive testing and research, and health benefits shown in clinical studies. It highlights features such as no artificial flavors, sweeteners, or fillers and being chlorine bleach free. The summary also notes Shaklee's investment in research and development, product guarantees, and supplement options for nutrition, weight management, and home cleaning.
The document summarizes the key aspects of Shaklee products, including their focus on natural ingredients, extensive testing and research, and health benefits shown in clinical studies. Some highlights include over 50 years of proven success with natural products, $250 million invested in research and development, and a landmark study showing long-term Shaklee supplement users had better health than non-users.
This document provides an overview of cannabis products and sales training. It discusses topics such as Colorado cannabis laws, health and safety standards, identifying customers and checking IDs, privacy practices, effects of cannabis, recommending different cannabis products like flower, edibles, concentrates, and alternatives. It also covers dispensary basics, gauging consumer tolerance, potency and dosing, product weight conversions, and restrictions on how much product can be sold. The textbook aims to educate cannabis sales associates and limit the spread of misinformation.
The document discusses several topics related to improving drug quality including:
1) Evidence from clinical trials and real world use is key to determining drug effectiveness but quality can deteriorate after marketing authorization without a strong quality management system.
2) Errors must be eliminated through quality by design in development and operational excellence, and companies must continuously improve rather than just fixing problems.
3) Digital transformation, identifying critical quality attributes, and moving to more flexible and integrated quality systems will help address issues and improve patient outcomes.
India's first Int'l Conference on Best Practices in Pharma Microbiology Biocon
This is the first time that Pharmig, an international Pharmaceutical Microbiology think tank based out of the UK is organizing a conference on the "Best Practices in Pharma Microbiology" for the first time in India. You can register
by sending an email to maxine@pharmig.org.uk. For booking a seat for the conference, please visit: http://bit.ly/1J4gtLh
This document discusses several challenges related to ensuring quality in Good Manufacturing Practices (GMP) and drug production, including issues with variability, contamination, and integrity. It notes that quality is complex and can be influenced by many factors across different functions. Oversight from reviewers, inspectors, and integrated teams is important. Collaboration between companies and governments is also key when it comes to labeling, agreements, and research review. The quality of drugs cannot be easily tested, so adherence to GMP regarding ingredients, facilities, and manufacturing processes is critical.
Similar to Opening Talk and Interactive Discussion (20)
The document discusses anti-thymocyte globulin (ATG), which is used for acute organ rejection. ATG is produced from rabbits that are inoculated with human T lymphocytes to trigger an antibody response. The antibodies produced in rabbits are then extracted, purified, and administered to patients to kill arrays of lymphocytes. Developing a process to characterize the target globulin and transferring knowledge will help establish protein production. Key challenges include maintaining clean environments and aseptic extraction, purification, and filling processes.
The document discusses establishing the OR Centre for Quality Sciences to provide consulting services to the pharmaceutical and biologics industries regarding quality, regulatory affairs, innovation, and technology. It aims to engage subject matter experts to support academia, industry, and government. The Centre will focus on shifting from a compliance to a quality culture and aligning with new regulatory expectations in a changing technological landscape with advances in areas like artificial intelligence and data sciences. It will provide training, reviews, audits, and other services to support quality systems, documentation practices, regulatory submissions, clinical trials, and more.
An article on contamination of Diethylene Glycol in Pharmaceuticals. Thanks to Dr. Ajaz S. Hussain for all teaching, sharing knowledge and supporting in professional development.
The document announces a training on demonstrating a quality management system during inspections to be held on September 30, 2023 in Kotri, Sindh. It will provide participants with techniques for showcasing compliance and procedures when regulatory audits occur. A list of attendees is included but not summarized for brevity.
The document provides tips for demonstrating a quality management system during an inspection. It advises being simple, clear, truthful, and confident when welcoming inspectors. Assign specific duties to staff and have flexibility. Listen fully to questions before responding, and don't argue - say you will look into issues. Practice mock inspections, recognize potential problems, and maintain your system daily.
The document discusses the services provided by the Centre for Quality Sciences, which include designing new and upgrading existing pharmaceutical manufacturing facilities, conducting GMP audits and training, assisting with regulatory submissions, and providing consulting services regarding quality systems, data integrity, and compliance strategies. The Centre's vision is to shift the industry towards a quality culture through knowledge sharing and facilitating discussions to develop strategic roadmaps. It aims to help companies strengthen quality compliance and sustain their quality management systems in the changing regulatory landscape.
The document discusses biomarkers, which are measurable indicators of biological states or conditions. It describes biomarkers as tools that can help facilitate medical product development. The document outlines different types, categories, and descriptions of biomarkers. It discusses how biomarkers can be qualified and approved by regulatory agencies like the FDA for specific contexts of use. The document provides examples of biomarkers that have been used for various purposes, such as assessing disease diagnosis, treatment effectiveness, and safety. It also summarizes some biomarkers that have been qualified or considered for qualification by the FDA.
1) The document discusses the evolution of ensuring drug quality from relying solely on testing to emphasizing proper manufacturing processes and controls.
2) It explains that without understanding the entire manufacturing process, one cannot say a drug is consistent in quality and purity or free of contamination.
3) Current good manufacturing practices (cGMP) help assure drug safety and efficacy by requiring facilities to control manufacturing operations through quality management systems and robust operating procedures.
The document discusses neurotoxicity and neurodegeneration in drug development. It notes that safety issues, especially related to the cardiovascular system and central nervous system, are among the most common reasons for drug development failure. Biomarkers for early detection of potential neurotoxicity could help improve success rates by facilitating safety screening earlier in the development process. The central nervous system is particularly vulnerable, as neurotoxicity is a frequent cause of failure in both pre-clinical and clinical phases of development.
Mr. Atiq ur Rahman has over 27 years of experience in pharmaceutical manufacturing and supply chain management. He has expertise in facility design, quality audits, and regulatory compliance. More recently, he has worked on data engineering, data acquisition, and applying data science concepts in pharmaceutical and other process industries. The presentation provides an overview of the industrial revolutions from Industry 1.0 to 5.0 and defines Pharma 4.0 as the convergence of people, systems, and data within a singular network powered by artificial intelligence. It discusses strategies for digital transformation and achieving digital maturity, including evaluating current technology needs and creating a roadmap with goals and timelines.
The document discusses the relationship between PIC/S and ICH and their roles in harmonizing GMP standards globally. PIC/S focuses specifically on GMP inspections and developing harmonized GMP standards and training inspectors. ICH focuses more broadly on safety, efficacy, quality and regulatory guidelines. Together they aim to promote reliance between regulatory authorities and open doors of trust through mutual recognition agreements and understanding of inspection systems. The document provides a comprehensive overview of their goals and collaboration to harmonize standards for patients worldwide.
The document discusses a presentation on quality issues observed by the FDA during inspections of pharmaceutical facilities in 2022. It notes the FDA observed deficiencies related to lack of written SOPs, insecure data, failure to investigate out of specification results, cleaning issues, and missing environmental monitoring programs. The document also presents a case study of a facility that had a significant media fill failure in November 2021 but did not initiate a recall until April 2022, exposing patients to risk. It describes poor aseptic techniques observed by FDA investigators during manufacturing operations.
The document discusses the pressure of real-world evidence on pharmaceutical regulatory science. It mentions the author's experience interacting with international regulatory agencies like the FDA, EU, Health Canada, and MHRA. It lists some references on topics like continuous manufacturing and real-time dissolution prediction. The document emphasizes that improving individual parts of a system will not improve the overall system, and that a systems approach to quality is needed.
This document provides information about an upcoming training session on Good Manufacturing Practices. The session will be held on October 16th in Karachi and will run from 9:00 am to 3:00 pm. It is aimed at pharmaceutical professionals with backgrounds in pharmacy, chemistry, microbiology and related fields. Experts from the US pharmaceutical industry will discuss advancements in manufacturing technology and emerging regulatory changes. The session will include tutorials, discussions, and Q&A to help participants better understand GMP requirements and ensure quality assurance. Participants will pay Rs. 10,000 or Rs. 5,000 depending on whether they are attending as part of their job. More details and contact information are provided.
This document contains questions and answers related to pharmaceutical quality and manufacturing. It discusses topics like clean hold time, dirty hold time, contamination control strategies, particles in injections, the differences between CMC, GMP, and continuous manufacturing. It also addresses questions about PIC/S, such as whether they issue membership, if inspections by one country are accepted by others, and that GMP certificates are issued by individual regulatory authorities rather than PIC/S.
This document discusses issues that may arise with generic drugs compared to innovator drugs. Bioequivalence studies only show equivalence at a single point in time and do not guarantee equivalence over the lifetime of the drug. Manufacturing the drug involves many variables like people, equipment, materials that could result in potency and dissolution differences compared to the innovator. The document provides data that showed increased hospitalization rates for certain generics compared to the innovator drug. It emphasizes the need for consistent quality manufacturing to ensure patient safety.
This document appears to be a scanned receipt from a restaurant in New York City listing various food and drink items purchased, with a subtotal of $86.62 and total including tax of $97.45. The receipt details a variety of appetizers, entrees, drinks and desserts ordered for multiple guests.
This document discusses key elements of good manufacturing practices (GMP) for pharmaceutical manufacturing. It covers topics like building layout, equipment, utilities, documentation, materials, production processes, packaging, quality systems, facilities, laboratories and ensuring the safety, efficacy and quality of pharmaceutical products. The overall message is that GMP provides a foundation and framework to establish process and quality control, validate operations, continuously improve and ultimately ensure that pharmaceutical products meet their intended quality standards.
This document discusses Good Manufacturing Practices (GMP) and how to ensure consistency, prevent mix-ups and contamination in the manufacturing of pharmaceutical products. It addresses that pharmaceutical quality is multivariate, while current testing approaches are univariate. Consistency is critical for drug efficacy and safety. Mix-ups can occur due to errors in inventory, labeling or simultaneous handling of similar materials. Contamination risks exist throughout the manufacturing process and can be controlled through cleaning validation, containment, dedicated equipment and facilities.
The document discusses the importance of good manufacturing practices (GMP) in ensuring drug quality and safety. It emphasizes that GMP provides documentation, traceability, trust, and predictability to assure the identity, quality, strength and correct manufacturing of drugs. While testing can verify quality, building quality into the manufacturing process through adherence to GMP is even more important. Ongoing monitoring processes like surveillance, complaint handling and recalls are also needed to protect patients even after a batch passes testing. Non-compliance with GMP can lead to disasters like mix-ups and contamination that endanger public health.
Integrity in leadership builds trust by ensuring consistency between words an...Ram V Chary
Integrity in leadership builds trust by ensuring consistency between words and actions, making leaders reliable and credible. It also ensures ethical decision-making, which fosters a positive organizational culture and promotes long-term success. #RamVChary
Public Speaking Tips to Help You Be A Strong Leader.pdfPinta Partners
In the realm of effective leadership, a multitude of skills come into play, but one stands out as both crucial and challenging: public speaking.
Public speaking transcends mere eloquence; it serves as the medium through which leaders articulate their vision, inspire action, and foster engagement. For leaders, refining public speaking skills is essential, elevating their ability to influence, persuade, and lead with resolute conviction. Here are some key tips to consider: https://joellandau.com/the-public-speaking-tips-to-help-you-be-a-stronger-leader/
Enriching engagement with ethical review processesstrikingabalance
New ethics review processes at the University of Bath. Presented at the 8th World Conference on Research Integrity by Filipa Vance, Head of Research Governance and Compliance at the University of Bath. June 2024, Athens
Originally presented at XP2024 Bolzano
While agile has entered the post-mainstream age, possibly losing its mojo along the way, the rise of remote working is dealing a more severe blow than its industrialization.
In this talk we'll have a look to the cumulative effect of the constraints of a remote working environment and of the common countermeasures.
Colby Hobson: Residential Construction Leader Building a Solid Reputation Thr...dsnow9802
Colby Hobson stands out as a dynamic leader in the residential construction industry. With a solid reputation built on his exceptional communication and presentation skills, Colby has proven himself to be an excellent team player, fostering a collaborative and efficient work environment.
A presentation on mastering key management concepts across projects, products, programs, and portfolios. Whether you're an aspiring manager or looking to enhance your skills, this session will provide you with the knowledge and tools to succeed in various management roles. Learn about the distinct lifecycles, methodologies, and essential skillsets needed to thrive in today's dynamic business environment.
Employment PracticesRegulation and Multinational CorporationsRoopaTemkar
Employment PracticesRegulation and Multinational Corporations
Strategic decision making within MNCs constrained or determined by the implementation of laws and codes of practice and by pressure from political actors. Managers in MNCs have to make choices that are shaped by gvmt. intervention and the local economy.
14. 3
Take a deep breath & imagine, have we recalled ?
Particles Contaminated
> 1 million liter injectable solution
recalled in a year in US
15. 3
Take a deep breath & imagine, have we recalled ?
Where it has gone? It is not in drain but in your vein
Particles Contaminated
> 1 million liter injectable solution
recalled in a year in US
17. Free access to information …. Globalization at its best
……… High moral & social acceptance
18. 4
Emergence & Evolution around
All options are open to progress
Be honest …..
Opportunities are expanding & barriers are reducing
19. Lets not only have a vision, but have a
spirit to design the dream
Get up & make speed fastest to chase your dream and
footsteps of success
20. The quality of drug indirectly relates to the
willingness of manufacturer, commercial
supplier, physician & society
Quality of drugs directly relates to the quality of
Regulatory Services
21. Its time to have a quick participation &
take a clear position
38. Antiseptics are
used to clean skin
such as swabs,
cleansing pads
It is powerful
against organisms
& saves from
infection
Situation
39. Antiseptics are
used to clean skin
such as swabs,
cleansing pads
It is powerful
against organisms
& saves from
infection
Should we have
concern for its
manufacturing
with regard to
microbes
Situation
40. Yes
No
Should we have CONCERN for manufacturing
of antiseptics with regard to microbial control
during manufacturing
43. Yes
Sampling plan should be scientifically sound &
representative of batch under test
Adequacy of mixing needs to be demonstrated by
regulation
Variability of location is a critical component of FG &
need to be evaluated
Science & risk based approach
44. Yes
Adequacy of blend mixing …. Prove it
Suitable juncture in manufacturing process from
where sampling was done
Prove that no difference exist between locations of
blending
How would you prove that it will not adversely
impact on the product performance
45. Yes
Powder thief has limitations and drawbacks
May cause disturbance to the powder blend
Powder segregation & sampling error
But widely used due to reliability in many cases
49. Situation
A non-sterile product
containing anti-
microbial preservative
in formulation
Got Out of
Specification for
total aerobic
plate count
Found within
specifications 2 weeks
later
51. No
Anti-microbial effectiveness test
Preservative must not be used as a substitute to GMP
Appropriate procedure to prevent objectionable
microorganisms in non-sterile products
Preservative is to reduce the viable microbial
population
52. No
Preservative may not be used to reduce initial OOS
result
Failure to meet established conditions must be
rejected
Preservative is used to reduce bio-burden of a multi-
dose formulation
Rejection is not an option but obligation
53. No
… to reduce microorganisms introduced during
manufacturing by addition of preservative
It is an opportunity to see & review manufacturing
process & identify the weakest area
Holding for 2 weeks is a great question that provides
opportunity …
Look back & see desensitization of Quality
Management System
54. Thank You We have deepest regards for your personal
time of Sunday in learning & building society